Detalhe da pesquisa
1.
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 22(1D): e240001, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244272
2.
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(1): 67-81, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652935
3.
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(12): 1281-1301, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38081133
4.
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Am J Hematol
; 98(11): 1751-1761, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37668287
5.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet
; 398(10297): 314-324, 2021 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175021
6.
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
J Natl Compr Canc Netw
; 20(1): 8-19, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34991075
7.
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(12): 1685-1717, 2020 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33285522
8.
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.
J Natl Compr Canc Netw
; 17(10): 1154-1165, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31590151
9.
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
Biol Blood Marrow Transplant
; 24(3): 478-485, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29079457
10.
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
Br J Haematol
; 182(2): 231-244, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29938772
11.
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Cancer
; 122(21): 3327-3335, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27433944
12.
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Haematologica
; 100(3): 357-62, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25596263
13.
Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma.
Am J Clin Oncol
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38483213
14.
Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.
Biol Blood Marrow Transplant
; 19(2): 260-5, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23073267
15.
Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study.
Br J Haematol
; 160(2): 199-206, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23151215
16.
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.
Clin Lymphoma Myeloma Leuk
; 23(9): e268-e276, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37301631
17.
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
Clin Lymphoma Myeloma Leuk
; 23(12): 882-888, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37716872
18.
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.
Transplant Cell Ther
; 29(4): 255-258, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36681151
19.
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
Nat Med
; 29(2): 422-429, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36690811
20.
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
Clin Lymphoma Myeloma Leuk
; 23(1): 68-77, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36357295